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SUMMARY
COVID-19 is the disease caused by the novel coronavirus, 
severe acute respiratory syndrome coronavirus 2 (SARS- 
CoV-2), which first arose in Wuhan, China, in December 
2019 and has since been declared a pandemic. The 
clinical sequelae vary from mild, self- limiting upper 
respiratory infection symptoms to severe respiratory 
distress, acute cardiopulmonary arrest and death. 
Otolaryngologists around the globe have reported a 
significant number of mild or otherwise asymptomatic 
patients with COVID-19 presenting with olfactory 
dysfunction. We present a case of COVID-19 resulting in 
intensive care unit (ICU) admission, presenting with the 
initial symptom of disrupted taste and flavour perception 
prior to respiratory involvement. After 4 days in the ICU 
and 6 days on the general medicine floor, our patient 
regained a majority of her sense of smell and was 
discharged with only lingering dysgeusia. In this paper, 
we review existing literature and the clinical course of 
SARS- CoV-2 in relation to the reported symptoms of 
hyposmia, hypogeusia and dysgeusia.
BACkgRoUnd
For many sick people with viral upper respiratory 
infections (URIs), the experience of eating food and 
perceiving flavour is often blunted either second-
arily from rhinitis and resulting nasal obstruction 
or from direct viral injury to olfactory neuroep-
ithelium. Retronasal olfaction, a combination of 
orthonasal smell and taste, is a sensory process that 
allows humans to perceive flavour, which is defined 
as the perception of anything beyond the five 
taste dimensions of food: sweet, salty, bitter, sour 
and umami.1 This process is temporarily impaired 
during URIs due to mucosal inflammation and 
congestion of the nasal passages, thus physically 
blocking the entry of odour and flavour molecules 
to the olfactory cleft.2 In contrast, post- URI olfac-
tory loss is a neural process that occurs due to viral 
insult2 and most commonly results in hyposmia late 
in the course of viral infection.3 This type of viral 
insult can result in either temporary loss of olfac-
tion or, in some cases, permanent loss of smell.
Severe acute respiratory syndrome coronavirus 
2 (SARS- CoV-2) is one of many pandemic coro-
naviruses that have been identified. The current 
outbreak of COVID-19 that began in Wuhan, China, 
has constituted a public health emergency of inter-
national concern, now creating a global impact with 
over 2.4 million cases to date.4 The clinical sequelae 
vary from mild and self- limiting URI symptoms to 
severe respiratory distress, acute cardiopulmonary 
arrest and death.5 Coronaviruses have previously 
been identified as a family of viruses associated with 
anosmia.6 Anecdotal evidence from otolaryngolo-
gists worldwide has suggested that otherwise mild 
cases of COVID-19 caused by the novel betacoro-
navirus, SARS- CoV-2, may be significantly associ-
ated with olfactory dysfunction.
We present a case of COVID-19 resulting in ICU 
admission, presenting with the initial symptom 
of disrupted taste and flavour perception prior to 
respiratory involvement. The purpose of this paper 
was to review the clinical course of SARS- CoV-2 in 
relation to the reported symptom of hyposmia and 
hypogeusia.
CASe pReSenTATion
A 59- year- old African–American female presented 
to our institution by ambulance on 29 March 2020, 
secondary to several days of shortness of breath, 
fatigue and loss of appetite. Medical history was 
significant for hypertension, hyperlipidaemia 
and asthma, requiring infrequent use of albuterol 
reported less than one time per month. Social 
history was notable only for a remote history of 
tobacco abuse, but she denied any current tobacco, 
drug or alcohol use. Of note, the patient did 
endorse that her husband, whom she lives with at 
home, was complaining of shortness of breath and 
a non- productive cough several days prior to her 
arrival. Her husband’s symptoms lasted only 3–4 
days and had resolved completely. She reported no 
past otolaryngological surgeries or use of any nasal 
sprays, or homeopathic or herbal medications.
Roughly a week prior to admission, the patient 
began to experience a subtle decrease in appetite 
and disinterest in food. These symptoms were 
isolated and preceded any indication that she was ill. 
Over the week prior to her presentation, the foods 
she normally enjoys tasted ‘bland and metallic’. The 
patient described her diet as ‘varied and including 
many spices and strong flavours, particularly using 
herbs in Jamaican and Caribbean cuisines’. When 
questioned further, she also admitted to a slowly 
diminishing ability to smell that progressed to 
complete anosmia in the absence of congestion or 
any other nasal symptoms. However, she did not 
make the connection to this early symptom and 
the subsequent respiratory distress until specifi-
cally questioned. She noted in particular that when 
preparing her normal meals, she could no longer 
appreciate any of the typical culinary aromas. 
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Figure 1 Chest radiograph, AP, day of admission. AP, anterior–
posterior; R, right.
Figure 2 Chest CT, axial (A) and coronal (B), day of admission.
Further, she could not smell any of her scented candles but did 
not think anything of it at that time. The patient denied any 
history of hyposmia or anosmia prior to this. It was not until 
a few days later when she developed a non- productive cough, 
malaise, shortness of breath and chest tightness that ultimately 
prompted her to call 911. On transit to the hospital via ambu-
lance, the patient had an initial SpO2 of 68% on room air, and 
she was later placed on supplemental oxygen.
Review of symptoms was negative for any nasal obstruction, 
rhinorrhea, epistaxis, and nasal or head trauma. She endorsed 
shortness of breath, malaise and chest tightness as mentioned 
previously. On admission, the patient was afebrile and saturating 
adequately on 5 L supplemental oxygen via nasal cannula. The 
patient appeared fatigued and mildly distressed, and physical 
exam was notable for bilateral wheezes and rales, most predomi-
nant at the lung bases bilaterally. The patient had no appreciated 
mucosal or turbinate hypertrophy in the nasal cavity and other-
wise had a normal head, eyes, ears, nose and throat examination.
inveSTigATionS
Laboratory values were significant for lactate dehydrogenase 
(410), erythrocyte sedimentation rate (42) and C reactive protein 
(192.1). Basic metabolic panel, liver function, renal function, 
myocardial enzymes and serum procalcitonin were otherwise 
normal. Tests for influenza A/B and Legionella were negative. 
A SARS- CoV-2 nucleic acid amplification test (NAAT) was 
taken by nasopharyngeal swab. A chest radiograph (see figure 1) 
followed by a high- resolution CT of the chest were performed, 
images of which reported multiple patchy ground- glass opacities 
in bilateral subpleural areas (see figure 2).
TReATMenT
Based on the overall clinical picture, the patient remained on 
contact and droplet precautions and isolation as it was assumed 
that she did have COVID-19. On the consult of our infectious 
disease physician and checking the patient’s corrected QT interval 
(QTc), the patient was empirically treated with the experimental 
therapy of hydroxychloroquine 400 mg two times per day for 
1 day followed by 200 mg two times per day for 4 days, as well 
as azithromycin 500 mg two times per day for 1 day followed by 
250 mg two times per day for 4 days.
The patient was subsequently transferred from the general 
floor to the ICU on the night of admission due to increased 
oxygen requirements with significant desaturations. The patient 
was initially placed on a non- rebreather and transitioned to 
continuous positive airway pressure (CPAP). On the advice of 
our pulmonologist, she remained on CPAP and intravenous 
steroids were initiated. The decision of early and pre- emptive 
intubation was discussed with our staff, but the patient did not 
display significant and continual signs of respiratory distress to 
necessitate this. While the patient was in the ICU, the result of 
the SARS- CoV-2 NAAT was positive for detection of the virus 
on 2 April 2020.
oUTCoMe And Follow-Up
The patient remained in the ICU for 4 days and was subsequently 
downgraded to the general floor when it was felt that her respi-
ratory status was improving, as she no longer required CPAP. 
On discharge on 8 April 2020, 10 days following admission, the 
patient endorsed that she had regained a majority of her sense of 
smell and that her sense of taste was greatly improved, although 
she did state foods did taste ‘excessively salty’ but no longer tasted 
metallic as noted before. She was not retested for SARS- CoV-2 
prior to discharge but was advised to self- quarantine for 14 days 
on returning home. To limit exposure to the patient’s primary 
care physician, the patient was instructed to call her physician as 
an outpatient to review her hospitalisation. She was instructed 
to return to the emergency room only if she experienced severe 
symptoms of respiratory distress or other alarming symptoms. A 
timeline detailing our patient’s clinical course in relation to her 
gustatory and olfactory complaints is shown in figure 3.
diSCUSSion
SARS- CoV-2, a betacoronavirus, is an enveloped positive sense 
RNA virus7 that first arose in Wuhan, China, in December 2019. 
Officially declared a pandemic on 11 March by the WHO,8 
COVID-19, caused by the novel coronavirus SARS- CoV-2, has 
affected over 2.4 million patients globally and resulted in over 
169 000 deaths as of 20 April 2020.4
Throughout recent weeks, reports of anosmia as a symptom of 
COVID-19 have flooded the media. Otolaryngologists around 
the globe have reported a significant number of patients with 
COVID-19 presenting with olfactory dysfunction,9 but scien-
tific data have proven that a significant association has been 
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Figure 3 Timeline of our patient’s clinical course with COVID-19. CPAP, continuous positive airway pressure; ICU, intensive care unit; NAAT, nucleic 
acid amplification test.
limited. A recent study in Italy using a patient questionnaire 
found that approximately one- third (20 of 59) of patients hospi-
talised with COVID-19 reported some degree of olfactory or 
gustatory dysfunction.10 Another recently accepted publica-
tion also involving olfactory and gustatory questionnaires was 
conducted at 12 European hospitals.11 Among the 417 mild- 
to- moderate European patients with COVID-19 involved in 
the Lechien et al study, 85.6% and 88.0% reported olfactory 
and gustatory dysfunction, respectively. The majority (65.7%) 
of patients reported olfactory dysfunction occurring after the 
appearance of general ears, nose and throat symptoms; however, 
11.8% of patients in this study reported olfactory dysfunction 
appearing before any other symptoms, suggesting anosmia 
may be important for early COVID-19 detection. They did not 
assess the prevalence of gustatory dysfunctions appearing as the 
first symptom, similar to how our patient presented. Addition-
ally, olfactory dysfunction was not significantly associated with 
rhinorrhea or nasal obstruction,11 hinting that the mechanism by 
which SARS- CoV-2 causes anosmia may be distinguishable from 
that of other common URI- causing viruses. However, Lechien et 
al did find significant associations between olfactory outcomes 
and several variables, including a significant association between 
fever and anosmia (p = 0.014). Furthermore, women were 
proportionally more affected by hyposmia or anosmia compared 
with men (p < 0.001).11 While more data are needed to determine 
if gender is a predisposing factor to the development of anosmia, 
the predilection for women in this study may be explained by sex 
dimorphisms in the olfactory bulb itself. A past study involving 
postmortem brains conducted in Brazil found that women have 
more neurons in the olfactory bulb.12 The higher suscepti-
bility of women to develop olfactory and subsequent gustatory 
dysfunction may also be related to sex differences in inflamma-
tory cytokine production.13 Future studies exploring gender and 
additional demographic differences in patients with COVID-19 
who experience anosmia are warranted.
The study of anosmia in COVID-19 has not been limited 
to Europe. Using a questionnaire sent out to over 10 000 resi-
dents in all provinces of Iran, a study that is now in preprint 
found that there is a significant correlation between anosmia 
and COVID-19 in the different provinces.14 However, reports 
of anosmia in Asia have not been robust. To our knowledge, 
Mao et al’s study, which details the neurological manifestations 
of 214 patients hospitalised with COVID-19 in Wuhan, China, 
is one of the only studies that mention olfactory and gusta-
tory dysfunction as symptoms associated with SARS- CoV-2.15 
In contrast to the European studies, only 5.1% and 5.6% of 
patients in Mao et al’s study reported hyposmia and hypogeusia, 
respectively.15 Earlier studies originating from the virus’ original 
epicentre of Wuhan have failed to mention effects on olfactory 
and gustatory sensation at all.16 17 This evokes many questions 
regarding the significance of anosmia and why it seems to be 
so prevalent in European populations yet hardly addressed in 
Asian papers. One explanation may be explained by variation 
in the SARS- CoV-2 genome. Analyses have revealed two major 
types of SARS- CoV-2, S and L, which are defined by their single- 
nucleotide polymorphisms.18 The L type was more prevalent 
in early stages of the outbreak in Wuhan, but its frequency has 
decreased.18 Emerging studies have also demonstrated continued 
evolution of SARS- CoV-2 in regard to its surface proteins, 
particularly the spike glycoprotein.19 20 This glycoprotein is 
necessary for binding cell receptors and thus determines host 
tropism,19 20 which may explain the potential clinical differences 
between patients of distinct demographic areas. Another possi-
bility is that patients with COVID-19 in the Asian population in 
fact did have anosmia with associated hypoguesia and dysguesia, 
yet these symptoms went un- noticed or under- reported. Unlike 
the loss of sight, which is readily apparent to others, anosmia can 
be particularly insidious and go unnoticed. As in the case of our 
patient, she did not realise she had anosmia until her perception 
of flavour and ability to enjoy foods were affected. For patients 
who eat primarily bland foods, such as white rice, which is a 
staple of the Chinese diet, anosmia and its subsequent impair-
ment on retronasal olfaction may not be evident. The need for 
further scientific study involving validated smell tests to deter-
mine the significance is apparent. The implications of hyposmia 
and the overall use of olfactory performance measures to either 
support or diagnose the prognosis in COVID-19 go beyond the 
acute disease state itself. It is well known in the literature that 
individuals with persistent olfactory dysfunction are at partic-
ular risk for nutritional deficiencies, development of depres-
sion and other psychiatric disorders, and the inability to detect 
certain ‘warning/danger’ odours like natural gas, smoke, spoiled 
foods and other noxious gases.21 On 22 March 2020, a state-
ment released from the American Academy of Otolaryngology–
Head and Neck Surgery (AAO- HNS), ‘Anosmia, hyposmia, and 
dysgeusia in the absence of other respiratory disease such as 
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patient’s perspective
This section highlights the patient’s direct quotes regarding the 
initial presentation of her disease, the progression that led her to 
the ICU and her eventual improvement and discharge from the 
hospital.
 ► ‘My husband was initially sick with what we thought was a 
cold. We were keeping up with the COVID-19 news and did 
not think that his symptoms could be it, because other than 
going to the grocery store, we had no direct contact with 
anyone. I then started to get really winded and began to 
cough. It was not until I spoke to the doctor at the hospital 
when I realized that my sense of taste and smell were off. 
Everything I was eating tasted off although they were recipes 
I made frequently. I did not know that my loss of smell was 
related to COVID’.
 ► ‘When the doctors told me I may have COVID I was very 
nervous and feared for my life. Everything that I heard on the 
news made me even more concerned about this. I had also 
wondered if my husband did in fact have COVID in the first 
place but got over it’.
 ► ‘I am thankful to have noticed early on to come to the 
hospital when I started having issues breathing as I believe 
my outcome would be a lot worse hadn’t I called 911’.
learning points
 ► Anosmia, dysgeusia and hypogeusia appear to be early 
presenting symptoms of COVID-19 in select patients that may 
occur prior to respiratory symptoms.
 ► While only recently added to the Centers for Disease Control 
and Prevention’s list of symptoms and not yet considered 
stand- alone symptoms that warrant COVID-19 testing, new- 
onset anosmia, hypogeusia and/or dysgeusia (especially in 
the absence of nasal congestion) should prompt strict self- 
isolation to limit presumptive viral spread.
 ► For many, the experience of smell and its lack thereof can 
be particularly insidious and go relatively unnoticed without 
large disruption in day- to- day life.
 ► As clinicians, we need to be keen on these subtle and 
overlooked symptoms of COVID-19, especially when objective 
tests for anosmia are not readily available to most providers.
 ► Although purely anecdotal evidence for the relationship 
between COVID-19 infection and the symptoms of hyposmia 
and hypogeusia, these remain concerning symptoms and 
prompt further investigation.
allergic rhinitis, acute rhinosinusitis, or chronic rhinosinusitis 
should alert physicians to the possibility of COVID-19 infection 
and warrant serious consideration for self- isolation and testing 
of these individuals’. On 26 March, the AAO- HNS released an 
anosmia reporting tool to assess for the significance of these 
symptoms in the diagnosis and progression of COVID-19.22 In a 
study analysing the first 237 of the tool’s entries, Kaye et al found 
that anosmia was present in 73% of subjects prior to COVID-19 
diagnosis and was the initial symptom in 26.6%. The most 
common symptoms to present before anosmia included cough 
(41%), malaise (39%), fever (38%) and headache (37%). Gastro-
intestinal (GI) distress was the least likely symptom to present 
before anosmia, occurring in 10% of patients.23 Similar to olfac-
tory dysfunction, patients with COVID-19 presenting with GI 
symptoms have garnered particular media attention and have 
been subject to a recent study. In a study conducted among three 
hospitals in China, 18.6% of patients with COVID-19 presented 
with a GI- specific symptom, including diarrhoea, vomiting or 
abdominal pain. They also found that patients with COVID-19 
may present with digestive symptoms, even in the absence of 
respiratory symptoms, although this occurred only in <1% of 
patients.24 Similarly, in a study conducted in the USA involving 
116 patients with confirmed SARS- CoV-2 infection, 31.9% of 
patients reported GI symptoms. This included loss of appetite 
(22.3%), nausea/vomiting (12.0%) and diarrhoea (12.0%) as the 
most common GI symptoms. None of the patients in this study 
developed isolated GI symptoms or GI symptoms as an initial 
manifestation of SARS- CoV-2 infection.25 Although more data 
are needed, it seems that anosmia and hypogeusia may be more 
likely as initial symptoms in COVID-19.
Additional studies using objective olfactory and gustatory tests 
are necessary to establish the significance of anosmia and hypo-
geusia in patients with COVID-19. Nonetheless, preliminary 
research suggests that gustatory or olfactory complaints during a 
viral pandemic should not be ignored. In a study based in the USA 
using a survey sent out to both patients positive for COVID-19 
and patients negative for COVID-19 with influenza- like symp-
toms, smell and taste loss were reported in 68% (40/59) and 
71% (42/59) of subjects positive for COVID‐19, respectively, 
compared with 16% (33/203) and 17% (35/203) of patients 
negative for COVID‐19 (p<0.001). Their results showed these 
chemosensory impairments were at least 10- fold more common 
in COVID-19- positive cases than COVID-19- negative cases, 
both presenting with similar influenza- like symptoms.26 While 
the authors of this study did not reveal how many of these 
patients tested positive for influenza virus,26 past studies have 
demonstrated that influenza is not significantly associated with 
change in smell.27 Furthermore, postviral olfactory disorders due 
to other common viruses has an estimated prevalence of around 
11%–40%,28 which appears much less common than that seen 
with SARS- CoV-2 infection according to existing studies. Future 
research should also investigate the frequency of olfactory and 
gustatory dysfunctions in patients infected with influenza and 
other common viruses, in order to confirm the significance of its 
correlation with COVID-19.
Our unique patient case and the aforementioned literature 
highlight the importance of the physicians’ ability to iden-
tify these subtle and sometimes unnoticed symptoms of this 
pandemic- creating virus. Peer- reviewed scientific literature 
is needed to further elucidate this early finding and to better 
understand the overall clinical course of SARS- CoV-2.
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